BTAI News and Press, BioXcel Therapeutics Inc. From 09/18/25

NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualificatio...

2025-09-10 18:41:42 ET BioXcel Therapeutics, Inc. (BTAI) Discuses on SERENITY At-Home Pivotal Phase 3 Safety Trial Results Conference September 10, 2025 02:00 PM ET... Read the full article on Seeking Alpha For further details see: BioXcel Therapeutics, Inc. (BTAI) Discuses ...

BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (p<.0001)...

NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present a c...

A look at the top 10 most actives in the United States Walgreens Boots Alliance Inc. (WBA) rose 0.5% to $11.98 on volume of 449,116,186 shares Top KingWin Ltd (WAI) rose 23.8% to $0.14 on volume of 363,164,388 shares TNF Pharmaceuticals Inc. (TNFA) rose 15.5% to $0.09 on volume of 301,890,2...

2025-08-27 14:00:33 ET Sharps Technology Extends Rally, Surges 54% on Solana Treasury Strategy Sharps Technology, Inc. ( STSS ) jumped another 54.36% to lead the PRISM Emerging MedDevices Index , building on yesterday's announcement of a $400M private placement to establish ...

2025-08-27 08:26:08 ET More on BioXcel Therapeutics Seeking Alpha’s Quant Rating on BioXcel Therapeutics Historical earnings data for BioXcel Therapeutics Financial information for BioXcel Therapeutics Read the full article on Seeking Alpha For...

BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SER...

BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SER...

NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will host an investor call and live webcast at 8 a.m. ET, ...